Form 4: Enliven COO Sells Shares Under 10b5-1 Plan

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold common stock totaling 6,667 shares on November 7, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of common stock.
• The transactions occurred on November 7, 2025.
• A total of 6,667 shares were sold across two separate transactions.
• The first transaction involved 6,054 shares sold at a weighted average price of $17.3503 per share, with prices ranging from $16.825 to $17.8248.
• The second transaction involved 613 shares sold at a weighted average price of $17.9371 per share, with prices ranging from $17.835 to $18.265.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024.
• Following these transactions, Anish Patel indirectly beneficially owns 269,974 shares of common stock through The Patel / Dong Family Trust, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sale of common stock by the Chief Operating Officer was conducted under a pre-arranged Rule 10b5-1 trading plan. Such planned transactions are generally considered routine liquidity events and do not typically signal new positive or negative developments for the company.

Future Outlook

NA

Industry Context

NA

Key Dates

Recommendation

The sale of shares by the Chief Operating Officer was executed under a pre-arranged 10b5-1 trading plan, which suggests a planned liquidity event rather than a reflection of new negative company developments. Such routine insider sales typically do not warrant a change in investment recommendation.

Keywords

Enliven Therapeutics, ELVN, Anish Patel, Insider Sale, Form 4, 10b5-1 Plan, Common Stock